Introduction
Since enzyme-specific synthetic peptide substrates were introduced for serine proteases, the field of coagulation enzymology has undergone a dramatic development. Although it has only been a few years since the first chromogenic tripeptide, Bz-Phe-Val-Arg-pNA' (S-2160) was introduced by Svendsen et a!. (9, 10) . Tables 1 and 2 
Application of Synthetic Peptides in Clinically Important Coagulation Parameters

Monitoring of antithrombin-IlI (AT-Ill).
The antithrombin-Ill activity in plasma is measured by use of thrombinspecific substrates such as S-2238 (H-n-Phe-Pip-Arg-pNA), chromozym-TH (Tos-Gly-Pro-Arg-pNA), or CBS 34.47 (H-i> CHG-But-Arg-pNA).
A known amount of thrombin is incubated with a sample of diluted plasma in buffer containing heparin.
The CBS 31.39
S-2251
Chromozym P CBS 30.41
ChemIcal structure
Tos or CBz-Gly-Pro-Arg-pNA 
Plasminogen
Satisfactory, all reagents are available. Standardization needed.
a2-Antsp!asmin
Reagents are not readily available. Availability of plasmin is limited.
Two kits available.
Heparin
Only measures absolute concentrations of heparin. Of questionable benefit for monitoring therapeutic heparinization.
Factor X
Reliable methods are available. Useful in the management of oral anticoagulants. Standardization needed.
Prothrombin (factor II)
Reliable assays available.
Prekal!ikrein
Satisfactory, all reagents available. Diagnostic significance yet to be established.
Factor Xa
Satisfactory. Standardization needed.
a2-Macrog!obulin
plasminogen in plasma reacts with a known amount of streptokinase to form the plasminogen-streptokinase complex (P-SK). Secondly, the amidolytic activity of P-SK complex is determined with S-2251, chromozym-PL, or CBS 30.41 as substrate.
The #{163}4405/min is proportional to the amount of plasminogen. In case of fluorogenic substrates, the fluorophore released after the action of SK-plasminogen action is measured to quantify the plasminogen. Prekallikrein. Prekallikrein (Fletcher factor) is quantified after the plasma being tested is activated, with the subsequent formation of the active enzyme, kallikrein (EC 3.4.21.8). The activity of this enzyme is proportional to the amount of prekallikrein present in plasma. Different activatore that have been used to activate prekallikrein include dextran, ellagic acid, and micronized silica. The various substrates used for these assays include S-2302 (H-LI-ProPhe-Arg-pNA), chromozym PK (Bz-Pro-Phe-Arg-pNA) and CBS 33.27 (H-n-Phe-Gly-Phe-Arg-pNA).
Antiplasmin.
Prekallikrein
(plasma) activator> kallikrein
08-2302 chromozym PK, or CBS 33.27
Factor Xa. Under normal circumstances the trace amount of Xa that is formed in blood is instantaneously inhibited by the many inhibitors present in plasma. However, during certain activated states of coagulation where the inhibitors are consumed, higher concentrations of activated factor Xa can be detected. Factor Xa can readily cleave various synthetic substrates to release pNA in proportion to the amount of Xa that is present in the plasma sample.
Factor Xa + RPNAa -a R-COOH + pNA 05-2337 5-2222, or CBS 31.39
a2-Macroglobulin.
a2-Macroglobulin is quantified indirectly through trypsin inhibition.
Boehringer Mannheim has recently provided a kit that contains a Tris HC1 buffer, trypsin, aprotinin, and chromozym-Try (Z-Val-Gly-ArgpNA). Aprotinin (Trasylol) is used to inhibit the activity of trypsin after a specific incubation period with the plasma a2-macroglobulin.
Results of Clinical Evaluation 14) , all of which are based on the same principle outlined above.
Citrated plasma is preferred over serum as the sample to be used to measure AT-HI, because some AT-Ill is consumed during the clotting process. We find that values for AT-Ill in samples of normal serum vary widely, and values for serum are as much as 30% lower than those for plasma samples from the same individual. Although immunological methods are being used to quantitate antithrombin-Ill (15), our data show that there is a good correlation between immunological methods and functional methods only for samples from normal individuals.
In pathok'gical states such as disseminated intravaseular coagulatio (DIC), hypercoagulable state, and liver dseases, the two results will differ considerably. Thus it is best to monitor the AT-rn by use of a functional method (16) , except for individuals with thrombotic complications who are suspected of having a hereditary deficiency of antithrombin-III, in whom it is useful to measure AT-rn by both techniques.
In Table 5 we compare the chromogenic, fluorogenic, and immunological methods as used to measure AT-Ill in 100 patients with various liver diseases. Obviously, results by the various amidolytic methods correlate well, but the immunologic methods gave higher results-not surprisingly, because, when active serine proteases are complexed with AT-Ill, the AT-Ill molecule retains its immuno-reactivity but loses its function. Table 6 shows a comparison of the thrombin and Xa methods for measuring heparin cofactor. The AT-Ill-hepatin complex also can inhibit activated factor X, so this enzyme can also be used in the assays for AT-Ill. In our data on 25 ostensibly normal individuals, results by the two During the last few years, an exhaustive clinical evaluation of the diagnostic efficacy of many of the newer amidolytic assays has been underway at this institution. Some preliminary results were published earlier (12) . Additional studies on assays of antithrombin-III, plasminogen, a2-antiplasmin, heparin, and factor X are now discussed here. methods were similar. However, for abnormal individuals the AT-rn value was higher by the Xa method than by the thrombin method. The heterogeneity of factor X may be responsible for this discrepancy. Although one can use factor Xa in the AT-Ill assay, the best results are obtained with pure human a-thrombin.
Antithrombin-III (heparin cofactor
Most coagulation factors are standardized in terms of percentage of the value for normal human plasma; thus it is best to express the results of functional AT-Ill measurements in these terms, because it relates to the physiological consumption of AT-Ill. The question of availability of a pure (or other) AT-Ill standard remains unsolved. In the immunological method, AT-Ill concentration is expressed in terms of mass concentration (milligrams per deciliter), but in assays based on function, only the inhibitory action of AT-Ill is measured. The amount and functionality are not always the same, and vary widely in pathological states. (12) . From the standpoint of diagnostic efficacy in acquired disorders, the functional methods offer fast, reliable assays.
Factor X assays. With the advent of factor Xa-specific substrates, many different methods for the quantitation of factor X have been proposed (26, 27) . It is also known that functional activity of factor X is decreased during therapy with oral anticoagulants, and that these decreases correlate with the prothrombin time and their anticoagulant effect (28). We evaluated the factor X method in normal persons, patients with liver diseases, and in those treated with oral anticoagulant drugs. As shown in Table 11 , for 10 normal persons the results of the amidolytic and clot-based assays correlated well, whereas for patients with liver diseases and those treated with oral anticoagulant drugs the amidolytic assays gave higher results. It is now known that during therapy with anticoagulants and in liver disease a defective decarboxylated form of factor X, which is devoid of coagulant activity, is formed. It is not known, however, whether the decarboxylated form of factor X can be activated by Russell's viper venom and exhibit amidolytic activity. Clinical data on the quantification of factor X are promising, and a multicenter study has presented convincing evidence that results for factor X can be reliably used as an index of oral anticoagulant effect on the coagulation system (27,28).
The prothrombin time has been used for over a quarter of a century to monitor therapy with orally administered anticoagulants. The amidolytic method: a kit from KabiVitrum. Stockholm, Sweden. The immunologic method: same as described in Table 9 . Because patients may have different and fluctuating concentrations of these proteins, the therapeutic responses vary widely. In our studies we have not found a good correlation between the measured concentrations of heparin and the activated partial thromboplastin time. Quantitation of heparin by amidolytic methods may be useful in the following: #{149} standardization of heparin preparations #{149} mini-dose heparin therapy where the efficacy of clot based assays is minimal #{149} protamine neutralization of heparin #{149} cross referencing of heparin preparations Table 13 shows a comparison of results obtained by three different amidolytic methods for the quantitation of heparin in plasma sampled from 25 patients being treated with 
Method
Mean (and SD)
A total of 25 plasma samples were evaluated for heparin quantitated in terms of USP units/mL. Mean activated partial thromboplastin time value for these plasmas: 78 ± 0.13 s.
heparin
and with values for activated partial thromboplastin time ranging from 55 to 110 s. Results by the amidolytic methods inter-compared well, but the activated partial thromboplastin time varied widely for these samples. We believe that measurement by these methods is not applicable to monitoring of therapeutic heparinization, because the results differ so much from those by standard methods of clotting appraisal.
The pharmacokinetics of heparin can be reliably measured with these assays; however, currently it is best to monitor therapy with heparin by using a coagulation method.
Performance
Characteristics of Various Amidolytic
Assays for Coagulation Parameters It is quite evident that the chromogenic method showed the better performance characteristic in all these assays. Results by the fluorometric method varied more. Abnormal samples tended to show greater variation in both the clotbased and Protopath methods. In the plasminogen and ATIll assays the immunological methods provided excellent results. These results suggest that the chromogenic methods reliably measure AT-Ill, plasminogen, heparin, and factor X. However, the interpretation of the results of these assays, and their standardization and diagnostic efficacy, must be individually determined.
Synthetic Peptide Assays for Monitoring the Defects of Extrinsic and Intrinsic Pathways of Coagulation
Several assays based on the use of thrombin-specific peptide substrates have been proposed for the amidolytic equivalents of prothrombin time and activated partial thromboplastin time. All of these methods involve the same principle as the clotting assays: the test plasma is activated with either thromboplastin or activator-cephaloplastin mixture and the thrombin activity so generated is measured by use of thrombin-specific synthetic substrates such as BzPhe-Val-Arg-pNA (S-2160), H-D-Phe-Pip-Arg-pNA (S-2238), Tos-Gly-Pro-Arg-pNA (chromozym TH), and H-o-CHG-ButArg-pNA (CBS 34.47). These substrates and their free peptide forms inhibit the amidolytic action of bovine Xa, human Xa, and Xa generated by Russell's viper venom in the following order: S-2160 > S-2238 > Sarc-Pro-Arg-pNA chromozym TH. A new substrate for thrombin, Pyro-GluPro-Arg-pNA (S-2366), and a plasminogen activator (tissue) substrate, H-D-Ile-Pro-Arg-pNA (S-2288), both inhibit bovine and human Xa more weakly. Tos-Gly-Pro-Arg-pNA, Sarc-Pro-Arg-pNA, and H-n-Ile-Pro-Arg-pNA were found to produce a 10% inhibition of the activator-generated amidolytic activity of Xa at the concentrations used in the prothrombin time and activated partial thromboplastin time assays. The synthetic-substrate equivalent assays are more sensitive than the existing prothrombin time and activated partial thromboplastin time assays and provide useful information on the total amount of thrombin generated in each assay. Our results suggest that amidolytic equivalent assays for prothrombin time and activated partial thromboplastin time are feasible and may eventually be suitable for clinical use. However, proper selection of a peptide substrate is important, because some of the throm-
Automation of Synthetic Substrate Methods
Because synthetic-substrate methods are based on the release or suppression of the release of a chromophore or fluorophore, or both, an enzyme analyzer such as is routinely used in clinical chemistry laboratories can also be used to evaluate coagulation. Because standardization and quality control are major problems in coagulation testing, an automated instrument may prove to be very useful in resolving many of the current difficulties.
The analyses performed by these instruments are based on the biochemical principles of enzymology.
Many of the coagulant variables will soon be measured on the basic kinetic principles of enzymology, and may be automatable.
A reliable system with a turnaround time of about 10 mm offers a great advantage to acute care/critical care units.
Because both AT-Ill and plasminogen are altered during acute episodes of thrombotic and fibrinolytic disorders, their assay can be used as markers and may help in the management of these patients.
The introduction of automated coagulation testing of this type represents a bridge between The synthetic substrates lend themselves extremely well to the assay of the enzymes of the coagulation and related systems and are equally useful in the assay of the regulators of these systems. The demonstration that these tests are clinically useful is the first step in their adoption as routine laboratory methods. More clinical studies comparing the older methods with these newer ones are needed, but we think that all indica-tions at present are that the methods are well suited for routine use.
